Rydapt Midostaurin Capsule

Description

Midostaurin 25mg is a brand-name prescription medication. It’s approved to treat the following conditions in adults: Newly diagnosed acute myeloid leukemia (AML) in people with a certain genetic mutation. AML is a type of cancer that’s found in your blood and bone marrow. Midostaurin is given to people with AML who have an abnormal (mutated) FLT3 gene. For this use, Midostaurin is used in combination with chemotherapy drugs. Certain types of systemic mastocytosis. This condition affects certain blood cells called mast cells. In some cases, it can lead to blood cancer. Midostaurin can be used alone to treat the following types of systemic mastocytosis: aggressive systemic mastocytosis (ASM) systemic mastocytosis that occurs with a form of cancer called associated hematological neoplasm (SM-AHN) mast cell leukemia (MCL), which is a type of cancer that may develop from ASM Midostaurin comes as capsules that are taken by mouth twice daily. It contains the drug midostaurin, which belongs to a class of drugs called kinase inhibitors. (A class of drugs describes medications that work in the same way.) Midostaurin isn’t considered a chemotherapy drug. Chemotherapy refers to traditional drugs used to treat cancer. These drugs typically affect both cancer cells and normal cells in your body. Midostaurin , on the other hand, is a targeted drug. It’s designed to work mainly on cancer cells. FDA approval In 2017, the Food and Drug Administration (FDA) approved Midostaurin for use. It was the first targeted therapy drug approved to treat AML. Effectiveness In a clinical study, Midostaurin was effective in treating AML. People in this study were given either Midostaurin or a placebo (treatment with no active drug). Both groups of people were also given chemotherapy drugs. The results showed the following: People taking Midostaurin were 23% more likely to still be alive after at least 3.5 years than were people taking the placebo. About 50% of the people taking Midostaurin went at least 8 months without having certain complications caused by their cancer. In comparison, about 50% of people taking the placebo went at least 3 months without having certain complications caused by their cancer. In another clinical study, Midostaurin was effective in treating certain types of systemic mastocytosis. In this study, 21% of people taking Midostaurin alone had complete remission* or partial remission.** These results were reported after six cycles of treatment. (The length of these treatment cycles varied.) * With complete remission, the people had an absence of mutated (abnormal) mast cells. ** With partial remission, the people had reduced activity of mutated mast cells. Midostaurin generic Midostaurin is available only as a brand-name medication. It’s not currently available in generic form. A generic drug is an exact copy of the active drug in a brand-name medication. Midostaurin contains the active ingredient midostaurin. Midostaurin cost As with all medications, the cost of Midostaurin can vary. The actual price you’ll pay depends on your insurance plan, your location, and the pharmacy you use. Your insurance plan may require you to get prior authorization before approving coverage for Midostaurin . This means that your doctor and insurance company will need to communicate about your prescription before the insurance company will cover the drug. The insurance company will review the request and let you and your doctor know if your plan will cover Midostaurin . If you’re not sure if you’ll need to get prior authorization for Midostaurin , contact your insurance company.